Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think they they are just smelling the stench of the slaughter house as the truck pulls up to unload them. They're nervous alright!
They'd probably cancel the shareholder meeting, do a private placement on the cheap and then reschedule the meeting if they thought that might happen though.
Yeah, hopefully the comp package is shot down even if the shelf is approved. Dan might be more responsible with funds if he suffers like the rest of the company's shareholders.
Good question
There's too many trials to keep track of any more.
It was 50 percent in those patients who got three doses. Continuous dosing should be very good.
Very well could happen, After all axal is a P3 construct so there is definitely the opportunity to make a lot of money. First right of refusal doesn't stop the clock for Astra indefinitely.
Astra could just outright buy the construct to use with their checkpoint inhibitor exclusively. They are no doubt seeing data with the high dose version of their drug in real time. The results could be very good.
I think it's all related to the first right of refusal with regard to our P3 starting. In one of the recent PRs, advaxis said they were planning on a second P3 for metastatic cervical can
cer. They are obviously waiting on some dealings with Astrazeneca to conclude.
I personally think everything other than prostate is already spoken for and most likely by the same partner.
Quick question, let's say the company was about to be bought and the buying company owned the short shares through various investment banks. Would the short have to be covered if the buying entity owned most of the short?
I agree, someone's cheating, it's obvious.
Pretty obvious at this point the SP is being moved around by HFT in an effort to create selling. I totally agree!
Good summation of the current situation!
I'm pretty sure at this point the company isn't saying what they may or may not be doing with regard to the FDA. I think think the company may actually have a decent chance of EU approval based off what they have said and done with regard to PRs and bringing in a new vice president who specializes in EU approval and actually has a track record of getting it done in the EU. They also finished the plant well ahead of time.
Unless we get a hundred million up front, might be why he went ahead and drug the stock down to get his options.
Could possibly explain the hold up with dosing as well.
Don't forget we're being used in conjunction with SOC as an adjuvant. If the company who's product has SOC makes an offer for AXAL, Dan would have to present that offer to Astrazeneca as I believe they have first right of refusal for AXAL.
Looks like maybe they are waiting for the combo high dose p2 to finish up then modify p3 to include the check point inhibitor in a massive deal.
Providing the 10mg combo version is doing well, JMO.
I believe the P3 is for locally advanced cervical cancer, not cancer free if my thinking is correct. We are being used as an adjuvant to SOC. I could totally see Astra locking up the construct to prevent SOC from becoming tougher to replace and gaining a longer time period of exclusivity.
You ever stop to think that the 10mg combo trial with Astra so almost done and that they are liking what they are seeing. P3 might very well get modified to include a check point inhibitor after Astra buys the construct.
I think in this case, it could be very good.
So what's the IND worth in the form of a milestone payment? That's what everyone should be wondering.
Not only is Amgen paying for the trials but we'll be getting milestones along the way to the tune of 500 million dollars. There may very well be no more dilution to the common stock.
Aduro, had a positive conf call this AM, that's probably also helping.
Price action does look good, fingers crossed our mgmt get behind an upward move
Dan is an attorney, so it makes sense for him to want a retainer from shareholders to do his job as CEO and carry out his fiduciary duties.
I think it's good FBG is letting Dan know we haven't forgot. The weakness is not entirely about the sector.
Yeah, I agree, some of these shorts might lose their livelihood!
I agree that there is a short bubble in bios.
Honestly, if there was a large investor who didn't mind making huge enemies, they could take a large position in this stock forcing shorts to cover and drive the SP into the clouds, after which they could sell their position to a big pharmacy or to shorts who would be begging at that point.
None if the leading pharmas in cancer tx want these affordable effective alternatives on the market.
The only problem with asking for that is what is being pasted is verifiable information that goes to show a pattern of behavior with regard to our ceo. Not bashing my friend, long term verifiable data.
Nah, I'm convinced the SP will never move with Dan as CEO. If it is not clear by now, we're not the investors he's working for. If we were, 40% of our float would not be short. They know what will happen an when so no worries.
Yeah I would too but I don't think that will ever happen with the Dan the hedge fund patsy at the helm.
Hey, if that is what it takes to remove the parasite then so be it.
This whole situation is pretty simple, large manipulating investors need to remove Dan, Greg and Sara and hire management who is above reproach or the original investors will continue to shed light on the misgivings of current management to put it nicely with the SEC. Dan needs to give back the options he recently received as well . Things need to change and large investors need to get in line.
Anyway, I'm sure if the SEC were to investigate that whole 2014 debacle a lot of other things would probably come to light and we might be able to get some management who would work for us instead of thwmselves.
It's not surprising, everybody in upper management once worked at Imclone. People in upper management from Imclone went to jail.